ClinicalTrials.Veeva

Menu
E

Edelweiss Medics | Kyiv, Ukraine

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Retatrutide
Orforglipron
Tirzepatide
Molnupiravir
LY3471851
LY3502970

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling
Coronavirus Disease (COVID-19)
Drug: Placebo
Drug: Molnupiravir
Locations recently updated

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Tirzepatide
Drug: Placebo

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiova...

Begins enrollment this month
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
Merck Sharp & Dohme (MSD) logo
Nektar Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems